• About us
• Contact

Advertisement

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2451 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25  

Deal: Collaboration or Financing	Date
Constructive Biology–SEVERAL: investment, 202409 financing round Series A first closing $58m led by Ahren + OMX Ventures + Paladin Capital	2024-09-24
Lift BioSciences–SEVERAL: investment, 202409 financing round Series A first closing £10m	2024-09-24
Roivant–Organon: investment, 202409– acquisition of Dermavant Sciences by Organon $175m upfront + $1.025b milestones plus royalties incl product Vtama	2024-09-18
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries	2024-09-16
Solasta Bio–SEVERAL: investment, 202409 financing round Series A $14m led by Forbion BioEconomy Fund	2024-09-11
Formo Bio–SEVERAL: investment, 202409 financing round Series B $61m from existing + new investors	2024-09-10
NanoSyrinx–BGF: investment, 202409 financing round totalling £10m incl co-lead investor BGF	2024-09-10
NanoSyrinx–IQ Capital: investment, 202409 financing round totalling £10m incl existing + co-investor IQ Capital	2024-09-10
NanoSyrinx–Lilly: investment, 202409 financing round totalling £10m incl new + co-investor Eli Lilly	2024-09-10
NanoSyrinx–Meltwind: investment, 202409 financing round totalling £10m incl existing + co-investor Meltwind	2024-09-10
NanoSyrinx–Merck (DE): investment, 202409 financing round totalling £10m incl existing + co-lead investor M Ventures	2024-09-10
NanoSyrinx–Octopus Investments: investment, 202409 financing round totalling £10m incl existing + co-lead investor Octopus Ventures	2024-09-10
NanoSyrinx–SEVERAL: investment, 202409 financing round £10m co-led by BGF + Octopus Ventures + M Ventures	2024-09-10
NanoSyrinx–Zyme Communications: public relations, 202409 service existent by Zyme	2024-09-10
PhoreMost–SEVERAL: investment, 202409 financing round Series B extension $12m bringing total round to $50m led by Parkwalk Advisors	2024-09-10
Immunocore–Danaher: data management software, 202409– supply Genedata SDMS for discovery of TCR therapeutics	2024-09-05
Caresyntax–SEVERAL: credit, 202408 up to $100m growth debt facility	2024-08-15
Caresyntax–SEVERAL: investment, 202408 financing round Series C extension $80m	2024-08-15
Balderton Capital–SEVERAL: investment, 202408 announced $615m Early Stage Fund IX	2024-08-12
Balderton Capital–SEVERAL: investment, 202408 announced $685m Growth Fund II	2024-08-12
Exscientia–Recursion Pharmaceuticals: investment, 202408– merger announced with former Recursion shareholders holding 74% of combined company	2024-08-08
FCC Group–Carbios: PET biorecycling, 202408– letter of intent to study implementation of Carbios technology at UK-based plant of FCC Environment UK	2024-08-06
iotaSciences–SEVERAL: investment, 202407 equity financing round from existing + new investors for business expansion	2024-07-31
Flo Health–General Atlantic: investment, 202407 Series C minority investment >$200m from General Atlantic	2024-07-30
Montara Therapeutics–SEVERAL: investment, 202407 seed financing round $8m led by SV Health DDF + co-led by Two Bear Capital	2024-07-30
Deepc–SEVERAL: investment, 202407 financing round Series A extension €13m led by Sofinnova Partners + Bertelsmann Investments	2024-07-25
Deepc–United Kingdom (govt): investment, 202407 financing round Series A extension totalling €13m incl new + co-investor KHP Ventures	2024-07-25
Axa–Zyme Communications: public relations, 202406 service existent for Kadans Science Partner by Zyme	2024-07-24
AstraZeneca–Pinetree Therapeutics: protein degradation drugs, 202407– excl option + ww license agreem up to >$500m plus royalties for EGFR degrader	2024-07-23
Third Arc Bio–SEVERAL: investment, 202407 financing round Series A $165m led by Vida Ventures	2024-07-23
Smart rTMS–Neurocare: investment, 202407 acquisition of Smart TMS by Neurocare Group	2024-07-22
Asceneuron–GSK: investment, 202407 financing round Series C totalling $100m incl existing + co-investor GSK Equities Investments Ltd	2024-07-16
Asceneuron–SEVERAL: investment, 202407 financing round Series C $100m led by Novo Holdings	2024-07-16
Asceneuron–SR One: investment, 202407 financing round Series C totalling $100m incl new + co-investor SR One	2024-07-16
Huma Therapeutics–AstraZeneca: investment, 202407 financing round Series D totalling >$80m incl investor AstraZeneca	2024-07-16
Huma Therapeutics–Bayer: investment, 202407 financing round Series D totalling >$80m incl investor Leaps by Bayer	2024-07-16
Huma Therapeutics–HAT SGR: investment, 202407 financing round Series D totalling >$80m incl investor Hat Technology Fund 4	2024-07-16
Huma Therapeutics–Hitachi: investment, 202407 financing round Series D totalling >$80m incl investor HV Fund	2024-07-16
Huma Therapeutics–SEVERAL: investment, 202407 financing round Series D >$80m (alongside investments from industry partners since Series C)	2024-07-16
Pan Cancer T–Scius Communications: public relations, 202407 supply service existent by Scius Communications	2024-07-11
Myricx Pharma–Brandon Capital: investment, 202407 financing round Seires A totalling £90m incl existing + co-investor Brandon Capital	2024-07-08
Myricx Pharma–Cancer Research UK: investment, 202407 financing round Seires A totalling £90m incl new + co-investor Cancer Research Horizons	2024-07-08
Myricx Pharma–Carlyle: investment, 202407 financing round Seires A totalling £90m incl new + co-lead investor Abingworth	2024-07-08
Myricx Pharma–Lilly: investment, 202407 financing round Seires A totalling £90m incl new + co-investor Eli Lilly	2024-07-08
Myricx Pharma–Novo Group: investment, 202407 financing round Seires A totalling £90m incl new + co-lead investor Novo Holidngs	2024-07-08
Myricx Pharma–SEVERAL: investment, 202407 financing round Seires A £90m led by Novo Holidngs + Abingworth	2024-07-08
Myricx Pharma–Sofinnova: investment, 202407 financing round Seires A totalling £90m incl existing + co-investor Sofinnova Partners	2024-07-08
Myricx Pharma–United Kingdom (govt): investment, 202407 financing round Seires A totalling £90m incl new + co-investor British Patient Capital	2024-07-08
Venga Ventures–SEVERAL: investment, 202407– fund raising with max target size of €40m to €50m	2024-07-08
Beacon Therapeutics–SEVERAL: investment, 202407 financing round Series B $170m led by Forbion	2024-07-03
Mission Therapeutics–Optimum Strategic Communications: public relations, 202407 service existent by Optimum	2024-07-02
FairJourney Biologics–Partners Group: investment, 202407– acquisition of majority share in FairJourney by Partners Group from GHO Capital	2024-07-01
CatSci–Keensight Capital: investment, 202406 additional investment? by Keensight to support acquisition of Reach Separations by CatSci	2024-06-25
Reach Separations–CatSci: investment, 202406 acqusition of Reach Separations by CatSci Ltd with support from Keensight Capital	2024-06-25
iOnctura–SEVERAL: investment, 202406 financing round Series B €80m led by new investor Syncona Ltd	2024-06-20
Marea Therapeutics–SEVERAL: investment, 202406 financing round Series B led by Sofinnova Investments (combined value of Series A+B = $190m)	2024-06-18
Marea Therapeutics–SEVERAL: investment, before 202406 financing round Series A led by founding investor Third Rock Ventures	2024-06-18
Mondi–Traceless Materials: biomaterials, 202406– collab strategic partnership using traceless material for paper coating solutions	2024-06-18
Novo Group–Hikma: investment, 202406– acquisition $135m upfront + $50m milestones part of Xellia’s business incl Cleveland plant + Zabreg RnD Center	2024-06-17
Amber Therapeutics–8VC: investment, 202406 financing round Series A totalling $100m incl existing + co-investor 8VC	2024-06-10
Amber Therapeutics–F-Prime: investment, 202406 financing round Series A totalling $100m incl new + co-investor F-Prime Capital	2024-06-10
Amber Therapeutics–Intuitive Ventures: investment, 202406 financing round Series A totalling $100m incl new + co-investor Intuitive Ventures	2024-06-10
Amber Therapeutics–Lightstone Ventures: investment, 202406 financing round Series A totalling $100m incl new + co-investor Lightstone Ventures	2024-06-10
Amber Therapeutics–New Enterprise Associates: investment, 202406 financing round Series A totalling $100m incl new + lead investor NEA	2024-06-10
Amber Therapeutics–Oxford Science Enterprises: investment, 202406 financing round Series A totalling $100m incl existing + co-investor OSE	2024-06-10
Amber Therapeutics–SEVERAL: investment, 202406 financing round Series A $100m led by NEA	2024-06-10
Brandon Capital–Hesta (AU): investment, 202406 first closing of Brandon Capital Fund VI totalling AUD270m incl existing investor Hesta	2024-06-04
Brandon Capital–Hostplus: investment, 202406 first closing of Brandon Capital Fund VI totalling AUD270m incl existing investor Host Plus	2024-06-04
Brandon Capital–SEVERAL: investment, 202406 first closing of Brandon Capital Fund VI at AUD270m (US$180m) incl investors HESTA + Hostplus	2024-06-04
Kyowa Kirin–Annogen: gene therapy development, 202406– collab research €na using SuRE technology to develop promoters for HSC gene therapies	2024-06-04
SolasCure–Zyme Communications: public relations, 202406 service existent by Zyme	2024-06-03
ExpressionEdits–Acequia Capital: investment, 202405 seed financing round totalling $13m incl co-investor Acequia Capital	2024-05-29
ExpressionEdits–Amino Collective: investment, 202405 seed financing round totalling $13m incl co-investor Amino Collective	2024-05-29
ExpressionEdits–BY Capital: investment, 202405 seed financing round totalling $13m incl co-investor BlueYard Capital	2024-05-29
ExpressionEdits–Hawktail: investment, 202405 seed financing round totalling $13m incl co-investor Hawktail	2024-05-29
ExpressionEdits–KKH Advisors: public relations, 202405 service existent by KKH Advisors	2024-05-29
ExpressionEdits–Octopus Investments: investment, 202405 seed financing round totalling $13m incl co-lead investor Octopus Ventures	2024-05-29
ExpressionEdits–Redalpine: investment, 202405 seed financing round totalling $13m incl co-lead investor Redalpine	2024-05-29
ExpressionEdits–SEVERAL: investment, 202405 seed financing round $13m co-led by Octopus Ventures + Redalpine	2024-05-29
ExpressionEdits–Wilbe Capital: investment, 202405 seed financing round totalling $13m incl co-investor Wilbe Capital	2024-05-29
Eyebiotech–Merck (US): investment, 202405– acquisition of EyeBio for $1.3 upfront cash + $1.7b milestones	2024-05-29
En Carta Diagnostics–Andrew Lloyd Associates: public relations, 202405 service existent by ALA	2024-05-22
LabGenius–Atomico: investment, 202405 financing round Series B totalling £35m incl existing + co-investor Atomico	2024-05-21
LabGenius–Kindred Capital: investment, 202405 financing round Series B totalling £35m incl existing + co-investor Kindred Capital	2024-05-21
LabGenius–LG: investment, 202405 financing round Series B totalling £35m incl new + co-investor LG Corp	2024-05-21
LabGenius–Lux Capital: investment, 202405 financing round Series B totalling £35m incl existing + co-investor Lux Capital	2024-05-21
LabGenius–Merck (DE): investment, 202405 financing round Series B totalling £35m incl new + lead investor M Ventures	2024-05-21
LabGenius–Obvious Ventures: investment, 202405 financing round Series B totalling £35m incl existing + co-investor Obvious Ventures	2024-05-21
LabGenius–Octopus Investments: investment, 202405 financing round Series B totalling £35m incl new + co-investor Octopus Ventures	2024-05-21
LabGenius–SEVERAL: investment, 202405 financing round Series B £35m led by M Ventures	2024-05-21
Limula–SEVERAL: investment, 202405 seed financing round CHF6.2m led by LifeX Ventures	2024-05-21
BioVersys–GSK: investment, 202403 financing round Series C extension totalling CHF12.3m incl investor GSK as part of collab	2024-05-07
BioVersys–SEVERAL: investment, 202403 financing round Series C extension CHF12.3m bringing total Series C to CHF44.9m	2024-05-07
GSK–BioVersys: alpibectir, 202405– collab expansion to speed up development to treat tuberculosis	2024-05-07
Memo Therapeutics–ICR: public relations, 202405 service existent ICR Consilium is media contact	2024-05-07
Memo Therapeutics–Schroders: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Schroders Capital	2024-05-07
Memo Therapeutics–SEVERAL: investment, 202405 financing round Series C extension CHF20m bringing total Series C to CHF45m	2024-05-07
Locate Bio–BGF (GB): investment, 202404 financing round totalling £9.2m incl existing investor BGF	2024-04-29
Locate Bio–Mercia: investment, 202404 financing round totalling £9.2m incl existing investor Mercia Ventures	2024-04-29
Locate Bio–SEVERAL: investment, 202404 financing round £9.2m with Mercia Ventures + BGF	2024-04-29

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25  

Advertisement

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.